Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway

Oncology Letters

Volumn 9, Issue 2, 2015, Pages 837-844

  Xie, Xin ^a,b   Wu, Meng Yao ^a   Shou, Liu Mei ^a   Chen, Long Pei ^a   Gong, Fei Ran ^a   Chen, Kai ^a   Li, Dao Ming ^a   Duan, Wei Ming ^a   Xie, Yu Feng ^a   Mao, Yi Xiang ^a   Li, Wei ^a   Tao, Min ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANTHARIDIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NORCANTHARIDIN; PROTEIN KINASE C; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MTT ASSAY; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84918812739     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2711     Document Type: Article

References (36)

1. Wolfgang CL, Herman JM, Laheru DA, et al: Recent progress in pancreatic cancer. CA Cancer J Clin 63: 318-348, 2013.
2. Paulson AS, Tran Cao HS, Tempero MA and Lowy AM: Therapeutic advances in pancreatic cancer. Gastroenterology 144: 1316-1326, 2013.
3. Peng F, Wei YQ, Tian L, et al: Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol 128: 223-230, 2002.
4. Chen YN, Chen JC, Yin SC, et al: Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 100: 158-165, 2002.
5. Huan SK, Lee HH, Liu DZ, Wu CC and Wang CC: Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. Toxicology 223: 136-143, 2006.
6. Li W, Xie L, Chen Z, et al: Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci 101: 1226-1233, 2010.
7. Li W, Chen Z, Zong Y, et al: PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKalpha and sustained activation of the NF-kappaB pathway. Cancer Lett 304: 117-127, 2011.
8. Li W, Chen Z, Gong FR, et al: Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway. Eur J Cancer 47: 2654-2664, 2011.
9. Li W, Li DM, Chen K, et al: Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the alpha-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study. BMC Cancer 12: 547, 2012.
10. Millward TA, Zolnierowicz S and Hemmings BA: Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24: 186-191, 1999.
11. Janssens V, Goris J and Van Hoof C: PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15: 34-41, 2005.
12. Chen YJ, Kuo CD, Tsai YM, et al: Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs 19: 55-64, 2008.
13. Schweyer S, Bachem A, Bremmer F, et al: Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours. J Pathol 213: 72-81, 2007.
14. Tanaka T, Masuda H, Naito M and Tamai H: Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Anticancer Res 21: 2463-2469, 2001.
15. McClay EF, McClay MT, Monroe L, Jones JA and Winski PJ: A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Res 11: 309-313, 2001.
16. Sudo K, Monsma FJ Jr and Katzenellenbogen BS: Antiestrogen-binding sites distinct from the estrogen receptor: subecellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology 112: 425-434, 1983.
17. Lam HY: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118: 27-32, 1984.
18. O'Brian CA, Liskamp RM, Solomon DH and Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465, 1985.
19. Su HD, Mazzei GJ, Vogler WR and Kuo JF: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol 34: 3649-3653, 1985.
20. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
21. Mandlekar S and Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477, 2001.
22. Andrén-Sandberg A, Hoem D and Bäckman PL: Other risk factors for pancreatic cancer: hormonal aspects. Ann Oncol 10 (Suppl 4): 131-135, 1999.
23. Jordan VC and Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20: 253-278, 1999.
24. Tomao S, Romiti A, Massidda B, et al: A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Res 22: 2361-2364, 2002.
25. Eckel F, Lersch C, Lippl F, Assmann G and Schulte-Frohlinde E: Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. J Exp Clin Cancer Res 19: 295-300, 2000
26. Efferth T, Fu YJ, Zu YG, et al: Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem 14: 2024-2032, 2007.
27. Chan E, Tan M, Xin J, Sudarsanam S and Johnson DE: Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel 13: 50-65, 2010.
28. Jiang JC: English translation of terms of prescription-monarch, minister, assistant and guide. Zhongguo Zhong Xi Yi Jie He Za Zhi 30: 1105, 2010 (In Chinese).
29. Wang L, Zhou GB, Liu P, et al: Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105: 4826-4831, 2008.
30. Edmond KM, Kortsalioudaki C, Scott S, et al: Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379: 547-556, 2012.
31. Wu JJ, Ai CZ, Liu Y, et al: Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes. Curr Drug Metab 13: 599-614, 2012
32. Tseng YP, Wu YC, Leu YL, Yeh SF and Chou CK: Scutellariae radix suppresses hepatitis B virus production in human hepatoma cells. Front Biosci (Elite Ed) 2: 1538-1547, 2010.
33. Li HB, Ge YK, Zhang L and Zheng XX: Astragaloside IV improved barrier dysfunction induced by acute high glucose in human umbilical vein endothelial cells. Life Sci 79: 1186-1193, 2006.
34. Lan TH, Xu ZW, Wang Z, et al: Ginsenoside Rb1 prevents homocysteine-induced endothelial dysfunction via PI3K/Akt activation and PKC inhibition. Biochem Pharmacol 82: 148-155, 2011.
35. Zong Y, Ai QL, Zhong LM, et al: Ginsenoside Rg1 attenuates lipopolysaccharide-induced inflammatory responses via the phospholipase C-gamma1 signaling pathway in murine BV-2 microglial cells. Curr Med Chem 19: 770-779, 2012.
36. He CL, Yi PF, Fan QJ, et al: Xiang-Qi-Tang and its active components exhibit anti-inflammatory and anticoagulant properties by inhibiting MAPK and NF-kappaB signaling pathways in LPS-treated rat cardiac microvascular endothelial cells. Immunopharmacol Immunotoxicol 35: 215-224, 2013